CAP (College of American Pathologists). 2007. HER2 and you: Guidelines provided by CAP and ASCO. Northfield, IL: CAP.

Cartron, G., L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier. 2002. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc RIIIa gene. Blood 99(3):754–758.

CDC (Centers for Disease Control and Prevention). 2009. Genomic translation: ACCE model process for evaluating genetic tests. http://www.cdc.gov/genomics/gtesting/ACCE/index.htm (accessed September 10, 2009).

CFF (Cystic Fibrosis Foundation). 2009. Patient registry report. http://www.cff.org/research/ClinicalResearch/PatientRegistryReport/ (accessed September 28, 2009).

CMS (Centers for Medicare & Medicaid Services). 2009a. Medicare claims processing manual. Chap. 16, laboratory services. http://www.cms.hhs.gov/manuals/Downloads/clm104c16.pdf (accessed September 17, 2009).

CMS. 2009b. Medicare coverage database. http://www.cms.hhs.gov/mcd/indexes.asp (accessed September 28, 2009).

CMS. 2009c. Proposed decision memo for pharmacogenomic testing for warfarin response (CAG-00400N). http://www.cms.hhs.gov/mcd/viewdraftdecisionmemo.asp?from2=viewdraftdecisionmemo.asp&id=224& (accessed September 24, 2009).

Di Nicolantonio, F., M. Martini, F. Molinari, A. Sartore-Bianchi, S. Arena, P. Saletti, S. De Dosso, L. Mazzucchelli, M. Frattini, S. Siena, and A. Bardelli. 2008. Wild-type BRAC is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology 26(35):5705–5712.

EGAPP Working Group (Evaluation of Genomic Applications in Practice and Prevention Working Group). 2009a. Recommendations from the EGAPP Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer? Genetics in Medicine 11(1):66–73.

EGAPP Working Group. 2009b. Recommendations from the EGAPP Working Group: Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genetics in Medicine 11(1):15–20.

FDA (Food and Drug Administration). 1997. Medical devices; classification/reclassification; restricted devices; analyte specific reagents—FDA. Final Rule. Federal Register 62(225):62243–62260.

FDA. 2005. Drug-diagnostic co-development concept paper. Silver Spring, MD: FDA.

FDA. 2007a. Commercially Distributed Analyte Specific Reagents (ASRs): Frequently asked questions. http://www.cytometry.org/website_pages/FDA%20ASR%20rule%202007.pdf (accessed September 19, 2009).

FDA. 2007b. Draft guidance for industry, clinical laboratories, and FDA staff: In vitro diagnostic multivariate index assays. Rockville, MD: FDA.

FDA. 2009a. Intercenter agreement between the Center for Drug Evaluation and Research and the Center for Devices and Radiological Health. http://www.fda.gov/CombinationProducts/JurisdictionalInformation/ucm121177.htm (accessed September 28, 2009).

FDA. 2009b. Medical devices: General and special controls. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/GeneralandSpecialControls/default.htm (accessed September 23, 2009).

FDA. 2009c. Medical devices: In vitro diagnostics. http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/default.htm (accessed September 23, 2009).



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement